Unknown NA INTERVENTIONAL 2-arm NCT05584163

Pilot Study to Evaluate the Prevention and Safety of Doxorubicin-induced Cardiomyopathy Using Extracorporeal Shock Waves

Single-center, Randomized, Prospective Controlled Pilot Study to Evaluate the Prevention and Safety of Doxorubicin-induced Cardiomyopathy Using Extracorporeal Shock Waves in Breast Cancer Patients Using Doxorubicin Anticancer Drugs

Sponsor: Ewha Womans University Mokdong Hospital

Conditions Breast Cancer

Interventions Extracorporeal shock waves

Updated 6 times since 2022 Last updated: May 31, 2023 Started: Oct 1, 2020 Primary completion: Jun 30, 2023 Completion: Jun 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05584163, this NA trial focuses on Breast Cancer and remains ongoing. Sponsored by Ewha Womans University Mokdong Hospital, it has been updated 6 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown NA
Jun 2025 — Sep 2025 [monthly]

Unknown NA

Status: Recruiting → Unknown
Sep 2024 — Jun 2025 [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
Jul 2023 — Jul 2024 [monthly]

Recruiting NA

▶ Show 1 earlier version

Nov 2022 — Jul 2023 [monthly]

Recruiting NA

First recorded

Oct 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ewha Womans University Mokdong Hospital

Data source: Ewha Womans University Mokdong Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea